Why the study?
The association between postimplant tricuspid regurgitation and heart failure hospitalization in patients without heart failure or preexisting abnormal tricuspid regurgitation and pressure gradient remained unclear.
Does progressive tricuspid regurgitation after permanent pacemaker implantation increase the risk of heart failure hospitalization in patients without baseline heart failure?
Does progressive tricuspid regurgitation after permanent pacemaker implantation increase the risk of heart failure hospitalization in patients without baseline heart failure?
Progressive tricuspid regurgitation occurs in nearly one-fifth of patients after permanent pacemaker implantation and is associated with an increased risk of heart failure hospitalization.
Answers are grounded in this paper and cite their sources.
Progressive postimplant TR after PPM may raise HF hospitalization risk in patients without prior HF; hypothesis-generating and needs prospective validation.
BACKGROUND: The association of postimplant tricuspid regurgitation (TR) and heart failure (HF) hospitalization in patients without HF and preexisting abnormal TR and TR pressure gradient (PG) remain unclear. HYPOTHESIS: This study aimed to explore the clinical outcomes of progressive postimplant TR after permanent pacemaker (PPM) implantation. METHODS: A total of 1670 patients who underwent a single ventricular or dual-chamber transvenous PPM implantation at our hospital between January 2003 and December 2017 were included in the study. Patients with prior valvular surgery, history of HF, and baseline abnormal TR and TRPG were excluded. Finally, a total of 1075 patients were enrolled in this study. Progressive TR was defined as increased TR grade of ≥2 degrees and TRPG of >30 mmHg after implant. RESULTS: In 198 (18.4%) patients (group 1) experienced progressive postimplant TR and elevated TRPG, whereas 877 patients (group 2) did not have progressive postimplant TR. Group 1 had larger change in postimplant TRPG (group 1 vs. group 2; 12.8 ± 9.6 mmHg vs. 1.1 ± 7.6 mmHg; p < .001) than group 2. Group 1 had a higher incidence of HF hospitalization compared to group 2 (13.6% vs. 4.7%; p < .001). Preimplant TRPG (HR: 1.075; 95% confidence interval [CI]: 1.032-1.121; p = .001) was an independent predictor of progressive postimplant TR. CONCLUSIONS: After a transvenous ventricular-based PPM implantation, 18.4% of patients experienced progressive postimplant TR and elevated TRPG. Higher preimplant TRPG was an independent predictor of progressive postimplant TR.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: